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Background: Esophageal adenocarcinoma is a disease that has a high mortality rate, the only 
known precursor being Barrett’s esophagus (BE). While screening for BE is not cost-effective at 
the population level, targeted screening might be beneficial. We have developed a risk prediction 
model to identify people with BE, and here we present the external validation of this model.
Materials and methods: A cohort study was undertaken to validate a risk prediction model 
for BE. Individuals with endoscopy and histopathology proven BE completed a questionnaire 
containing variables previously identified as risk factors for this condition. Their responses 
were combined with data from a population sample for analysis. Risk scores were derived for 
each participant. Overall performance of the risk prediction model in terms of calibration and 
discrimination was assessed.
Results: Scores from 95 individuals with BE and 636 individuals from the general population 
were analyzed. The Brier score was 0.118, suggesting reasonable overall performance. The area 
under the receiver operating characteristic was 0.83 (95% CI 0.78–0.87). The Hosmer–Lem-
eshow statistic was p=0.14. Minimizing false positives and false negatives, the model achieved 
a sensitivity of 74% and a specificity of 73%.
Conclusion: This study has validated a risk prediction model for BE that has a higher sensitiv-
ity than previous models.
Keywords: Barrett’s  esophagus, risk prediction model, screening, validation
Introduction
Esophageal adenocarcinoma has a 5-year survival rate of <20%,1 making it a lethal 
disease. The proportion of patients with metastatic spread at the time of diagnosis has 
been increasing,2 potentially contributing to low survival rates. Barrett’s esophagus 
(BE), a condition where some of the lining of the distal esophagus undergoes a meta-
plastic change to resemble tissue similar to that normally found in the intestine,3 is 
the only known precursor to esophageal adenocarcinoma.1,4 BE progresses stepwise 
via low- and high-grade dysplasia to cancer.5
Screening for BE presents an opportunity to detect individuals with a greater risk 
of adenocarcinoma, facilitating targeted endoscopic surveillance potentially result-
ing in earlier diagnosis of high-grade dysplasia or early cancer, thereby allowing 
more effective interventions. Population-level screening for BE has not been shown 
to be cost-effective.4,6 Current recommendations are that screening for BE could be 
considered for men with chronic gastroesophageal reflux disease and two or more 
risk factors including >50 years, central obesity, first-degree family history of BE 
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or esophageal adenocarcinoma, a smoking history, and 
Caucasian race.7,8 This recommendation would still require 
substantial resources if screening were to be widespread.9 
Methods to further facilitate targeted screening have not been 
evaluated and might be of benefit.
We have previously developed and published a risk 
prediction model with internal validation.10 Briefly, a case–
control study was undertaken in 2015 to identify potential 
variables that might better predict BE. The resulting risk 
prediction model included the variables such as age, gender, 
individual history of hypertension, individual history of acid 
regurgitation, first-degree family history of reflux, number of 
alcoholic drinks per week, and body mass index (BMI). The 
model showed good discrimination (area under the receiver 
operating characteristic [AUC] 0.82; 95% CI 0.78–0.87) 
and calibration (Hosmer–Lemeshow test p=0.67) during 
development.10
However, for a model to be clinically applicable, it needs 
to be externally validated, as model performance gener-
ally decreases when applied to different populations.11 The 
purpose of this current study was to externally validate the 
accuracy of the previously developed risk prediction tool.10
Materials and methods
This study is reported according to the Transparent Reporting 
of a multivariable prediction model for Individual Progno-
sis Or Diagnosis (TRIPOD) checklist for prediction model 
development and validation.12 A cohort study was undertaken 
to validate the previously developed model. In November 
2016, potential new participants with BE were mailed study 
information, a self-reporting questionnaire, and a reply-paid 
envelope to return completed questionnaires. After 3 weeks, 
those who had not returned the questionnaire received the 
information again as a reminder; no further contact was made 
following this. Retrospective population data, people without 
BE, were obtained from a study undertaken in Queensland 
and reported in 2009.13 Participants were recruited from dif-
ferent institutions than the initial development group for the 
risk prediction model.
Ethics statement
Ethical approval was granted by the Southern Adelaide 
Clinical Human Research Ethics Committee (#433.14), 
the University of South Australia Human Research Ethics 
Committee (#0000033915), and QIMR Berghofer Medi-
cal Research Institute Human Research Ethics Committee 
(#P514). For the participants with BE, consent to use data 
was implied if the questionnaire was returned.
Study participants
Potential participants with BE were identified using the 
endoscopy database from the Royal Adelaide Hospital, a 
major tertiary hospital within South Australia, Australia. 
BE definition was the same used in the development of the 
model – that is, BE ≥2 cm with intestinal metaplasia (IM). 
Histological reports were used to confirm IM.
The population data were provided by QIMR Berghofer 
Medical Research Institute in Queensland, Australia. The 
data had been collected for a previous study of BE and 
the participants had provided written consent for the data 
to be used in subsequent studies. These participants lived 
in Queensland and had been recruited at random from the 
Australian Electoral Roll (voter registration is compulsory in 
Australia).13 They did not undergo an endoscopy to exclude 
BE, but respondents who answered “yes” to the question 
regarding previous BE diagnosis  were omitted from this 
study (1.24%). This is comparable with the prevalence of 
BE within the previous model development group (1.3%)10 
and aligns with the suggested prevalence of BE (1.2%–1.6%) 
within the general population.3
Questionnaire
The self-reported questionnaire for BE patients consisted of 
10 questions, 8 relating to the 7 predictors within the model 
(height and weight were collected to calculate BMI) and 
2 additional questions to capture participant demographic 
characteristics. These questions used in this validation study 
were identical to those from the derivation study. Importantly, 
the questionnaire items used for this validation study and the 
derivation study were based on those used in the Queensland 
study,13 which serves as an independent validation here.
Statistical analysis
Returned questionnaire information was entered into the 
Stata 14 software package (StataCorp, 2015, Stata Statistical 
Software: Release 14; StataCorp LP, College Station, TX, 
USA). BMI was then calculated (weight [kg]/Height [m]2). 
For BE participants, variables recording an individual’s his-
tory of reflux and hypertension were modified to calculate 
pre-BE status. For example, those diagnosed with hyperten-
sion following the diagnosis of BE were considered not to 
have hypertension for analysis, consistent with the process 
followed during the development phase.10 This information 
was then added to the population sample data.
The Queensland control population dataset contained 
all but one of the items required for the prediction equa-
tion, namely, family history of reflux. As such, this variable 
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was imputed by developing a predictive model for family 
history of reflux from the original series of controls from 
the development dataset, and then applying this model to 
the new Queensland control population. To do this, a boot-
strapped aggregated stepwise logistic regression process was 
undertaken to reduce the list of 12 potential predictors of 
family history of reflux to a smaller set of predictors.14 This 
involved taking 1000 bootstrapped samples and selecting 
those variables included in the model 500 or more times. Five 
variables remained at this stage as the best joint predictors 
of a family history of reflux, namely individual acid reflux, 
smoking, BMI, height, and history of hernia. Logistic regres-
sion, with a family history of reflux as the dependent variable 
and the other variables as independent variables, was then 
undertaken. A receiver operating characteristic analysis was 
performed, and this identified that a cutoff of ≥0.237 in the 
predicted value was indicative of a family history of reflux.
The resulting equation from the development population 
to obtain the predicted value for a family history of reflux was 
then applied to the Queensland population dataset, using the 
following formula: predicted = exp(x)/(1 + exp(x)), where x 
is the output from the equation for each individual. The 0.237 
cutoff was used to convert family history of reflux into a 0 
(no)/1 (yes) variable resulting in 80.24% without and 19.76% 
with a family history of reflux, which is comparable to the 
development population (75.64% without and 24.36% with).
Validation
The risk prediction model was run to generate participants’ 
probability of having BE. The formula used is as follows:
Probability of BE = exp(f)/(1 + exp(f))
where  “f ”  is  −7.003635 +  (0 .0645714×age)  + 
(0.8431104×gender) + (−0.9861185×history of hypertension) 
+ (1.051748×history of acid regurgitation) + (1.186615×fam-
ily history of reflux) + (0.2971902×alcoholic drinks per 
week) + (0.6125564×BMI).10 Table 1 provides the different 
predictor scorings.
Example of model in use
The following scenario of a BE patient demonstrates the 
model in practice: a 44-year-old male reports that he has 
been experiencing a sour taste in his mouth at times and he 
has been using antacid tablets (Quick-eze®; Nestlé Australia 
Ltd, Rhodes, NSW, Australia) for symptom relief. Lately, 
they have not been as effective in relieving the symptoms. 
His father had suffered from reflux; he drank an average of 
30 beers per week and his BMI was 28. Other observations 
were unremarkable and no other issues were found.
Using the coding in Table 1 and the model formula: 
f = −7.003635 + (0.0645714×44) + (0.8431104×1) + 
(−0.9861185×0) + (1.051748×1) + (1.186615×1) + 
(0.2971902×4) + (0.6125564×1).
The probability of BE=0.67; therefore, this person has a 
67% chance of having BE. The bold fonts indicate the score 
that has been given for each variable.
Assessment
The overall risk prediction model performance was initially 
assessed using the Brier score, a test of how well a prob-
ability prediction performs, by measuring the mean square 
error of the predicted probability of the patient having BE 
compared to their actual disease status, and is used for 
binomial outcomes. A score of zero (0) represents perfect 
performance, while a score of 0.25 represents a 50% chance 
of having BE.15 The model was then assessed for discrimina-
tion and calibration. Discrimination, the ability of the model 
to predict someone with BE or not, was assessed using the 
AUC.16 An AUC of 0.5 indicates random chance, the closer 
to 1.0, the more accurate the test is at discriminating a case 
from a non-case in any pair of individuals,16 in this case 
BE. Interpretation of AUC results can be further refined: 
0.51–0.69 least accurate, 0.7–0.9 moderately accurate, and 
>0.9 highly accurate.17 Calibration, how well the predicted 
Table 1 Scoring of predictors for BE risk prediction model
Risk factor Measure Scoring
Age (years) Continuous Continuous
Gender Female
Male
0
1
History of hypertension 
(treated with medication)
No
Yes
0
1
History of acid regurgitation  
(a sour taste from acid rising up 
into your mouth or throat)
No
Yes
0
1
First-degree family history of 
reflux
No
Yes
0
1
Alcoholic drinks per week Do not drink
≤4
5–13
14–27
≥28
0
1
2
3
4
BMI (kg/m2) <25.00
25.00–29.99
≥30.00
0
1
2
Abbreviations: BE, Barrett’s esophagus; BMI, body mass index.
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probabilities align with the observed probability of being an 
actual case, was assessed using the calibration curve, where 
a slope of 1 equals good alignment and a slope <1 indicates 
model overfitting,15 and the Hosmer–Lemeshow goodness-
of-fit test, where a larger p-value indicates a better fit1 and 
the Lowess smoother calibration plot.
Results
Two hundred seventy-one questionnaires were mailed to BE 
patients and 95 were returned (35% response rate). Data were 
available from 644 general population sample participants 
(58% response rate);13 of these, 8 had indicated a diagnosis 
of BE and hence were not included in this analysis, leaving 
636 population samples.
Demographics
Mean age for BE patients was 66.8 years (SD 10.5), with 
the population sample being 57.9 years (SD 11.3), p<0.001. 
No statistical difference was seen in gender of both groups 
(70.53% in the BE group and 64.47% in the population 
group were male [p=0.30]). Table 2 provides a summary of 
the demographic and clinical variables between patients with 
BE and the population sample.
Testing of the imputation formula for 
family history of reflux
The imputation equation was assessed. The AUC was 0.74 
(95% CI 0.67–0.82), Brier score was 0.154, and the calibra-
tion curve slope was 0.99 (p<0.001) with an intercept of 
4.14e-07 (p=1.0). This indicated that the imputation was 
moderately accurate at discriminating family history of 
reflux. Overall calibration was also reasonably good; how-
ever, there was a slight overprediction at the upper end of 
the calibration curve.
Validation
To assess overall risk prediction model performance, the 
Brier score was obtained (0.118), which indicated reasonable 
overall performance.15 The calibration curve slope was 1.14 
(p<0.001) with an intercept of −1.08 (p<0.001), indicating 
the model is not overfitted. The Hosmer–Lemeshow statistic 
was p=0.14, identifying that the predicted risks are not signifi-
cantly different from observed risks. The Lowess smoother 
calibration plot was derived (Figure 1). This shows the tool 
to be well calibrated in predicting those who are at ultrahigh 
risk (needing to be investigated) and those who are predicted 
to be at low risk (not needing investigation). False positives 
will be identified at the upper middle of the prediction range. 
The AUC was 0.83 (95% CI 0.78–0.87; Figure 2), with 74% 
sensitivity and 73% specificity. To maximize sensitivity and 
specificity, the Youden Index was calculated,18 providing the 
empirical cut off point (0.317955) to minimize false positives 
and false negatives.
Clinical applicability of the model needs to be considered 
with any prediction tool. The current study has calculated the 
number of patients who would be sent for endoscopy if vari-
ous probability thresholds were applied. Positive predictive 
values (PPV) and negative predictive values (NPV) were also 
calculated for each cut off point (Table 3). PPV identifies the 
probability of a person whose test results are positive will 
actually have the disease, while NPV shows the probability 
of the person whose test results are negative will be disease 
free.19 These were based on the estimated prevalence of 
undiagnosed BE within the general population (1.6%).3 This 
Table 2 Demographic and clinical information
Variables Barrett’s 
esophagus 
patients, n=95
Population 
sample, 
n=636
p-valuea
Age, years, mean (SD) 66.8 (10.5) 57.9 (11.3) <0.001
Gender, n (%)
 Male
 Female
67 (70.53)
28 (29.47)
410 (64.47)
226 (35.53)
0.30
History of 
hypertension, n (%)
 Yes
 No
 Missing 
33 (34.74)
62 (65.26)
0
91 (14.31)
539 (84.75)
6 (0.94)
<0.001
History of acid 
regurgitation, n (%)
 Yes
 No
 Missing
73 (76.84)
22 (23.16)
0
25 (3.93)
555 (87.26)
56 (8.81)
 
<0.001
First-degree family 
history of reflux, n (%)
 Yes
 No
 Missing
54 (56.84)
39 (41.05)
2 (2.11)
113 (17.77)
459 (72.17)
64 (10.06)
<0.001
Alcoholic drinks per 
week, n (%)
 Do not drink
 ≤4
 5–13
 14–27
 ≥28
 Missing
23 (24.21)
28 (29.47)
35 (36.84)
6 (6.32)
3 (3.16)
0
67 (10.55)
160 (25.16)
191 (30.03)
98 (15.41)
76 (11.94)
44 (6.92)
<0.001
BMI, kg/m2, n (%)
 <25.00
 25.00–29.99
 ≥30.00
 Missing
21 (22.11)
36 (37.89)
37 (38.95)
1 (1.05)
230 (36.17)
263 (41.35)
136 (21.38)
7 (1.10)
0.001
Note: ap-values were calculated using t-test for continuous variables and Fisher’s 
exact test for categorical variables.
Abbreviation: BMI, body mass index.
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indicates that the number of false positives will be high, while 
the number of false negatives will be negligible.
Discussion
We have validated a risk prediction model for BE, developed 
for use within primary health care to identify individuals who 
are at potentially higher risk and may benefit from further 
investigation.
Five BE risk prediction tools have been developed over the 
last 15 years, with varying results; however, none have been 
sufficiently accurate to implement in clinical practice.1,20–23 
Three of these models have now been validated (Table 4).1,22,24 
These results are on the low end of moderate accuracy at pre-
dicting BE.17 It has also been reported that tests with an AUC 
≤0.75 have minimal clinical usefulness.25 Therefore, none of 
the above mentioned models meet this clinical usefulness 
Predicted risk of Barrett’s esophagus
Bandwidth=0.8
Barrett’s esophagus vs population calibration plot
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Figure 1 Logistic calibration for predicted versus observed risk.
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Figure 2 Area under the receiver operator characteristic BE patients versus population.
Abbreviation: BE, Barrett’s esophagus.
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criterion. These models used statistical significance to deter-
mine the final variables, potentially negating some variables 
that could have improved the overall AUC.26,27
Using statistical significance alone (p<0.05) to select 
variables could potentially remove important predictors that 
have an association with the outcome, especially in small 
datasets.26,27 Variables associated with but not necessarily hav-
ing a causal link to the outcome should also be considered in 
the selection process, as these may not always be statistically 
significant during the analysis.27
To obtain the best performing predictors within our 
model, bootstrapping with stepwise logistic regression 
followed by aggregation was used rather than statistical sig-
nificance. This resulted in the inclusion of three predictors 
that have not been included in previous models: history of 
hypertension, family history of reflux, and the number of 
alcoholic drinks per week. The remaining variables within 
our model have been used in various combinations in other 
prediction models.1,20–23 This achieved an AUC of 0.83 on 
validation, indicating a moderately accurate test that might 
be clinically useful.17,25
Selecting a referral cut off point requires a balance 
between disease severity and cost. For a disease with a high 
mortality rate that could be reduced with early treatment, a 
higher sensitivity compared with specificity may be accepted 
for screening tests. However, the consequence is more people 
being sent for investigation, and a high false-positive rate. 
A higher specificity could be acceptable for diseases with 
low consequence as not identifying the disease may have 
minimal impact.28 While BE is not fatal, it can progress to 
adenocarcinoma (which carries a high mortality rate) at a 
rate between 0.3% and 0.6% per year.29 As the prevalence 
of BE is low within the general population with low adeno-
carcinoma progression rates,29 a higher specificity and PPV 
should be considered to reduce the number of costly and 
invasive endoscopies undertaken unnecessarily.
Table 3 Probability threshold performance in a general population
Probability threshold 
for having BE
Sensitivity (%) Specificity (%) Patients sent for 
endoscopy (%)
Positive predictive 
value (%)
Negative predictive 
value (%)
≥0.1 100 26 76 0.7 100
≥0.2 89 51 51.2 2.9 99.7
0.27a 77 67 35.1 3.7 99.4
≥0.3 74 71 31 4.0 99.4
0.317955b 74 73 29 4.3 99.4
≥0.4 64 82 19.9 5.5 99.3
≥0.5 53 88 13.6 6.7 99.1
≥0.6 49 94 7.5 11.7 99.1
≥0.7 30 98 3.0 19.6 98.9
≥0.8 15 100 0.5 100 98.6
≥0.9 3 100 0.1 100 98.4
Notes: aEmpirical cutoff from model development to minimize false positives and false negatives. bEmpirical cutoff from validation data to minimize false positives and false 
negatives.
Abbreviation: BE, Barrett’s esophagus.
Table 4 Comparison of previous risk prediction models for BE
Author (year) Country Sample size 
development
Development 
AUC
Sample size 
validation
Validation AUC
Gerson et al,21 (2001) USA 517 0.72 NA Not performed
Locke et al,20 (2003) USA 1009 0.76 NA Not performed
Thrift et al,1 (2012) Australia/USA 706 0.70 593 0.61
Rubenstein et al,23 (2013)a USA 822 0.72 1: 716
2: 302
3: 256
4: 118
1: 0.71
2: 0.70
3: 0.72
4: 0.70
Liu et al,22 (2014) UK 1603 0.81 478 0.64
Note: aValidation undertaken by an independent author on four datasets.24
Abbreviations: AUC, area under the receiver operating characteristic; BE, Barrett’s esophagus; NA, not applicable.
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If there were an intermediate step between the risk 
prediction tool and endoscopy, identifying the 30 out of 
100 people who warrant further investigation may be more 
acceptable. An example is the cytosponge, currently under 
investigation.30 This risk prediction model coupled with the 
use of nonendoscopic screening methods for BE (e.g., the 
cytosponge) has the potential of being clinically useful.
Current BE screening recommendations suggest that men 
with chronic gastroesophageal reflux disease and two or more 
risk factors, including >50 years, central obesity, first-degree 
family history BE or esophageal adenocarcinoma, a smoking 
history, and Caucasian race, should be considered.7,8 Others 
have suggested that this be reviewed and the age be lowered 
to <50 years of age for males,31 particularly if they have had 
gastroesophageal reflux disease symptoms from an early 
age.32 If this recommendation was adopted, it would place 
further pressure on already limited resources. We contend 
that using the proposed screening strategy described earlier 
could reduce this.
Potential limitations to this study include that the popula-
tion sample did not undergo an endoscopy to exclude BE; 
however, the prevalence identified is comparable to the 
suggested prevalence within the general population. As the 
estimated prevalence of BE within the general population is 
low,3 the magnitude of this effect would be minimal, with 2 
of the 636 participants used as controls potentially having 
BE. The population sample had been collected previously 
without asking about a family history of reflux, and therefore, 
this variable had to be imputed. This may produce different 
results compared with having this variable collected at the 
time. However, the model without family history of reflux 
had a pseudo-R-squared of 0.543, and the addition of this 
variable only added another 0.003 to the R-squared, indicating 
that a family history of reflux plays only a minor contribution 
to the predictive model. The development and validation of 
the model occurred within Australia, although from different 
geographical locations; thus, the results may vary if under-
taken in different countries due to differing sociodemographic 
factors. Finally, the low response rate within the BE group 
(35%) could potentially introduce a nonresponse bias. Ideally, 
a prospective trial should be undertaken to further validate 
these results.
In summary, this study externally validated a BE risk 
prediction model that shows higher sensitivity than previous 
models. These results are promising; however, a prospective 
trial should be undertaken to investigate the application of the 
model within clinical practice. If the model continues to per-
form well in prospective trials, it has the potential to improve 
the identification of patients at greater risk of having BE.
Acknowledgments
The authors would like to thank Dr Tom Laws, School of 
Health and Society, University of Salford, England, for his 
support. Assistance with accessing the endoscopy database 
to identify potential participants with Barrett’s esophagus 
was provided by The Department of Gastroenterology and 
Hepatology, Royal Adelaide Hospital.
The retrospective population dataset was collected as 
part of The Study of Digestive Health. Study of Digestive 
Health Investigators were as follows: Queensland Institute 
of Medical Research, Brisbane, Australia: David C White-
man, MBBS, PhD; Adele C Green, MBBS, PhD; Nicholas 
K Hayward, PhD; Peter G Parsons, PhD; Sandra J Pavey, 
PhD; David M Purdie, PhD; Penny M Webb, DPhil. Uni-
versity of Queensland, Brisbane, Australia: David Gotley 
FRACS; Mark Smithers FRACS. The University of Adelaide, 
Adelaide, Australia: Glyn G Jamieson FRACS. Flinders 
University, Adelaide, Australia: Paul Drew, PhD; David 
I Watson FRACS. Envoi Pathology, Brisbane, Australia: 
Andrew Clouston, PhD, FRCPA. The Study of Digestive 
Health was supported by grant number RO1 CA 001833 
from the National Cancer Institute. Its contents are solely 
the responsibility of the authors and do not necessarily rep-
resent the official views of the National Cancer Institute. CJI 
receives support through an Australian Government Research 
Training Program Scholarship.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC; Study of 
Digestive Health. A clinical risk prediction model for Barrett esophagus. 
Cancer Prev Res (Phila). 2012;5(9):1115–1123.
 2. Stavrou EP, McElroy HJ, Baker DF, Smith G, Bishop JF. Adenocarci-
noma of the oesophagus: incidence and survival rates in New South 
Wales, 1972–2005. Med J Aust. 2009;191(6):310–314.
 3. Zimmerman TG. Common questions about Barrett esophagus. Am Fam 
Physician. 2014;89(2):92–98.
 4. Whiteman DC, Appleyard M, Bahin FF, et al. Australian clinical practice 
guidelines for the diagnosis and management of Barrett’s esophagus 
and early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2015; 
30(5):804–820.
 5. Gopal DV, Reichelderfer M, Gaumnitz EA, Harter J, Jobe BA. Barrett’s 
esophagus: is screening and surveillance justified? Dis Manag Health 
Out. 2004;12(6):353–361.
 6. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy 
of a non-endoscopic screening test for Barrett’s oesophagus in primary 
care: cohort study. BMJ. 2010;341:c4372.
 7. Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of 
Gastroenterology. ACG clinical guideline: diagnosis and management 
of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50.
 8. Fitzgerald RC, di Pietro M, Ragunath K, et al. British society of gas-
troenterology guidelines on the diagnosis and management of Barrett’s 
oesophagus. Gut. 2014;63(1):7–42.
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
12
 o
n 
17
-A
ug
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical and Experimental Gastroenterology 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical and Experimental Gastroenterology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-and-experimental-gastroenterology-journal
Clinical and Experimental Gastroenterology is an international, peer-
reviewed, open access, online journal publishing original research, 
reports, editorials, reviews and commentaries on all aspects of 
gastroenterology in the clinic and laboratory. This journal is included 
on PubMed. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is all easy 
to use. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.
Dovepress
142
Ireland et al
 9. Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal 
adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(4):243–248.
 10. Ireland CJ, Fielder AL, Thompson SK, Laws TA, Watson DI, Esterman 
A. Development of a risk prediction model for Barrett’s esophagus in 
an Australian population. Dis Esophagus. 2017;30(11):1–8.
 11. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for 
the external validation of a multivariable prognostic model: a resampling 
study. Stat Med. 2016;35(2):214–226.
 12. Collins GS, Reitsma JB, Altman DG, Moons KM. Transparent reporting 
of a multivariable prediction model for individual prognosis or diagnosis 
(tripod): the tripod statement. Ann Intern Med. 2015;162(1):55–63.
 13. Smith KJ, O’Brien SM, Green AC, Webb PM, Whiteman DC; Study 
of Digestive Health. Current and past smoking significantly increase 
risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7(8): 
840–848.
 14. Brieman L. Bagging predictors. Mach Learn. 1996;24(2):123–140.
 15. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance 
of prediction models: a framework for traditional and novel measures. 
Epidemiology.2010;21(1):128–138.
 16. Cook NR. Statistical evaluation of prognostic versus diagnostic models: 
beyond the ROC curve. Clin Chem. 2008;54(1):17–23.
 17. Greiner M, Pfeiffer D, Smith RD. Principles and practical application 
of the receiver-operating characteristic analysis for diagnostic tests. 
Prev Vet Med. 2000;45(1–2):23–41.
 18. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its 
associated cutoff point. BiomJ.2005;47(4):458–472.
 19. Buttner P, Muller R. Epidemiology. 1st ed. South Melbourne, Australia: 
Oxford University Press; 2011.
 20. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict 
endoscopic findings in GERD? Gastrointest Endosc. 2003;58(5): 
661–670.
 21. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symp-
tom questionnaire to predict Barrett’s esophagus in patients with symptoms 
of gastroesophageal reflux. Am J Gastroenterol. 2001;96(7):2005–2012.
 22. Liu X, Wong A, Kadri SR, et al. Gastro-esophageal reflux disease 
symptoms and demographic factors as a pre-screening tool for Barrett’s 
esophagus. PLoS One. 2014;9(4):e94163.
 23. Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Bar-
rett’s esophagus among men. Am J Gastroenterol. 2013;108(3):353–362.
 24. Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB. 
External validation of the Michigan Barrett Esophagus Prediction Tool. 
Clin Gastroenterol Hepatol. 2017;15(7):1124–1126.
 25. Fan J, Upadhye S, Worster A. Understanding receiver operating char-
acteristic (ROC) curves. CJEM. 2006;8(1):19–20.
 26. Hendriksen JM, Geersing GJ, Moons KG, de Groot JA. Diagnostic 
and prognostic prediction models. J Thromb Haemost. 2013;11(Suppl 
1):129–141.
 27. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. 
Development, internal validation, and assessing the incremental value 
of a new (bio) marker. Heart. 2012;98(9):683–690.
 28. Akobeng AK. Understanding diagnostic tests 3: receiver operating 
characteristic curves. Acta Paediatr.2007;96(5):644–647.
 29. Schoofs N, Bisschops R, Prenen H. Progression of Barrett’s esophagus 
toward esophageal adenocarcinoma: an overview. Ann Gastroenterol. 
2017;30(1):1–6.
 30. Tan WK, di Pietro M, Fitzgerald RC. Past, present and future of Barrett’s 
oesophagus. Eur J Surg Oncol. 2017;43(7):1148–1160.
 31. Desilets DJ, Nathanson BH, Navab F. Barrett’s esophagus in practice: 
gender and screening issues. J Men’s Health. 2014;11(4):177–182.
 32. Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at 
onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J 
Gastroenterol. 2013;108(6):915–922.
 
Cl
in
ica
l a
nd
 E
xp
er
im
en
ta
l G
as
tro
en
te
ro
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
21
9.
20
2.
12
 o
n 
17
-A
ug
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
